| Autor: |
Keymeulen B; Academisch Ziekenhuis and Diabetes Research Center, Brussels Free University-VUB, Brussels, Belgium., Candon S, Fafi-Kremer S, Ziegler A, Leruez-Ville M, Mathieu C, Vandemeulebroucke E, Walter M, Crenier L, Thervet E, Legendre C, Pierard D, Hale G, Waldmann H, Bach JF, Seigneurin JM, Pipeleers D, Chatenoud L |
| Jazyk: |
angličtina |
| Zdroj: |
Blood [Blood] 2010 Feb 11; Vol. 115 (6), pp. 1145-55. Date of Electronic Publication: 2009 Dec 09. |
| DOI: |
10.1182/blood-2009-02-204875 |
| Abstrakt: |
Here we report a unique situation in which an early and synchronized Epstein-Barr virus (EBV) reactivation was induced by a 6-day course of treatment with a humanized CD3-specific monoclonal antibody in patients with recent onset of type 1 diabetes. The virologic and immunologic analysis demonstrated that this reactivation was transient, self-limited, and isolated, associated with the rapid advent of an EBV-specific T-cell response. The anti-CD3 antibody administration induced short-lasting immunosuppression and minor yet clear-cut signs of T-cell activation that preceded viral reactivation. Early posttransplant monitoring of renal and islet allograft recipients showed that no comparable phenomenon was observed after the administration of full-dose immunosuppressive therapy. This EBV reactivation remains of no apparent clinical concern over the long term and should not preclude further development of therapeutic anti-CD3 antibodies. This phenomenon may also direct new research avenues to understand the still ill-defined nature of stimuli triggering EBV reactivation in vivo. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
